Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 469 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR As More People with Cancer Use Medical Cannabis, Oncologists Face Questions... October 16, 2024 A ‘sponge on a string’ test to detect oesophageal cancer earlier July 31, 2020 School Teacher’s Breast Cancer Journey Inspired Her to Move to Australia... February 17, 2020 Por qué el registro de médula ósea necesita más donantes diversos... February 8, 2022 Load more HOT NEWS 6 Things to Know About Regrowing and Caring for Your Hair... Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer News digest – Genetic links to male breast cancer, bowel cancer... Access to Cancer Medicines and Clinical Trials Show Stark Variations Across...
